Medicus Pharma Ltd.

What they do

Medicus Pharma is a clinical-stage, multi-strategy biotech focused on accelerating development of therapeutic assets. Through its SkinJect subsidiary, it develops dissolvable microneedle arrays delivering doxorubicin for basal cell carcinoma and Gorlin Syndrome. Through its Antev subsidiary, it develops Teverelix, a GnRH antagonist for prostate cancer and acute urinary retention. The company has no approved products and generates no revenue from product sales.

Revenue drivers

• SkinJect (D-MNA) — Phase 2 study SKNJCT-003 reported 73% clinical clearance and 40% histological clearance in the D-MNA arm versus 38% clinical clearance in the device-only arm; later June 2026 update showed 64% clinical and 55% histological clearance in the 200 µg cohort. No revenue yet.
• Teverelix (Antev) — Phase 2b dose-optimization study in advanced prostate cancer cleared by FDA; optimized Phase 2 study design for recurrent acute urinary retention submitted; Phase 2a PRECISION-E2 planned in UAE. No revenue yet.
• Gorlin Syndrome program — Pursuing registrational Phase 2b study (SKNJCT-005); has filed for Orphan Drug and Rare Pediatric Disease designations. No revenue yet.

Recent performance

For the year ended December 31, 2025, the company reported a net loss of $47.3 million, up from $11.2 million in 2024, with diluted EPS of -$2.74. Operating cash flow was -$22.8 million for 2025 versus -$10.2 million in 2024. As of June 30, 2026, total assets were $27.1 million, total liabilities $28.8 million, and cash and equivalents $15.2 million, with shareholder equity of -$1.8 million. Topline results from SKNJCT-003 were announced in March 2026, with further updates in June 2026.

Strategy

The company is advancing SkinJect through clinical trials, targeting FDA alignment on a 505(b)(2) regulatory pathway for BCC. It acquired Antev in August 2025 to expand into prostate indications. It is exploring accretive acquisitions and partnerships across therapeutic areas with unmet needs. It is also pursuing rare-disease designations for Gorlin Syndrome and has established MDCX Holdings for secured promissory note transactions.

Risks

• Negative shareholder equity — As of June 30, 2026, total liabilities exceeded total assets (equity -$1.8 million), indicating potential solvency pressure.
• Clinical trial variability — SKNJCT-002 was paused after enrolling 7 of 15 subjects due to variability in array application, raising questions about device consistency.
• No approved products or revenue — The company has no commercial products and relies on external financing and partnerships to fund operations.
• Nasdaq listing risk — 8-K filings from April and May 2026 indicate delisting notices or listing-rule failures, which could affect stock trading.

Outlook

Management continues to advance SkinJect through Phase 2 and registrational studies, with FDA alignment on the 505(b)(2) pathway and pending Orphan Drug and Rare Pediatric Disease designations. It also expects to progress Teverelix with the planned PRECISION-E2 study in the UAE. The company's cash position of $15.2 million may fund operations only for a limited period given the current burn rate, and it may need to raise additional capital.